News from xencor, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 19, 2015, 08:00 ET

Xencor Appoints A. Bruce Montgomery, M.D. to Board of Directors

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Mar 16, 2015, 08:00 ET

Xencor to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Mar 02, 2015, 16:01 ET

Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock

Xencor, Inc. (NASDAQ: XNCR) today announced the completion of an underwritten public offering of 8,625,000 shares of its common stock, including...

Feb 25, 2015, 08:00 ET

Xencor, Inc. Prices Public Offering of Common Stock

Xencor, Inc. (NASDAQ: XNCR) today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock, offered at a...

Feb 23, 2015, 16:04 ET

Xencor, Inc. Announces Proposed Public Offering of Common Stock

 Xencor, Inc. (NASDAQ: XNCR) today announced that it intends to offer and sell, subject to market and other conditions, up to 5,500,000 shares...

Feb 19, 2015, 16:01 ET

Xencor Reports Fourth Quarter and Full Year 2014 Financial Results

 Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Feb 12, 2015, 08:00 ET

Xencor, Inc. to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Feb 05, 2015, 08:00 ET

Xencor to Webcast Presentations at Two Upcoming Conferences in February

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jan 29, 2015, 07:00 ET

Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity in Rheumatoid Arthritis

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jan 29, 2015, 07:00 ET

Xencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction of Serum IgE in Healthy Volunteers

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Dec 18, 2014, 08:00 ET

Xencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb Bispecific and Immune Inhibitor Technologies

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Dec 06, 2014, 23:00 ET

MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting

 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and Xencor Inc. (NASDAQ: XNCR) today announced the publication of final...

Dec 04, 2014, 08:00 ET

Xencor to Present at the 25th Annual Oppenheimer & Co. Healthcare Conference

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Nov 25, 2014, 08:00 ET

Xencor to Present at the 2014 Deutsche Bank BioFEST Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Nov 10, 2014, 16:01 ET

Xencor Reports Third Quarter 2014 Financial Results

 Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Nov 06, 2014, 09:09 ET

Xencor Provides Data Updates on XmAb Bispecific Antibody Programs and Announces Presentations at Upcoming American Society of Hematology 2014 Annual Meeting

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Nov 04, 2014, 08:00 ET

Xencor to Present at the 2014 Credit Suisse Annual Healthcare Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Nov 03, 2014, 08:00 ET

Xencor to Host Third Quarter 2014 Financial Results Webcast and Conference Call

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Oct 28, 2014, 16:00 ET

Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Sep 02, 2014, 08:00 ET

Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...